The first time I met Lloyd Old was in late 1976, several weeks after I had started a fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. With the adventure of experiencing life in New York City as my major goal, I had come to MSKCC without clearly defined plans, only with a vague idea to study immunology in the context of the pathogenesis and therapy of cancer. The id...

Downlo ent clinical trials show that combined oral dosing with estrogen and progestin increases the inciof breast cancer in postmenopausal women. Similarly, in a rat model system of mammary carciesis, the synthetic progestin medroxyprogesterone acetate (MPA) decreases latency and increases nce of 7,12-dimethylbenz(a)anthracene (DMBA)–induced mammary tumors. The goal of this was to compare the e...